Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521454 | 0.85 | GRM5 (0.53) | GRM5OPRL1 | |
| SCHEMBL2516774 | 0.81 | GRM5 (0.45) | GRM5AROPRL1OPRM1 | |
| SCHEMBL2515085 | 0.80 | GRM5 (0.51) | GRM5AROPRL1OPRM1 | |
| SCHEMBL2520679 | 0.79 | OPRL1 (0.45) | GRM5OPRL1OPRM1 | |
| SCHEMBL12235108 | 0.78 | GRM5 (0.67) | GRM5OPRL1OPRM1 | |
| SCHEMBL2518176 | 0.76 | GRM5 (0.60) | GRM5 | |
| SCHEMBL2516590 | 0.75 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2518298 | 0.75 | GRM5 (0.62) | GRM5 | |
| SCHEMBL2518095 | 0.75 | GRM5 (0.61) | GRM5 | |
| SCHEMBL2560735 | 0.73 | GRM5 (0.40) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20140155602-A1 | Arlethynyl Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155602-A1 | Arlethynyl Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8618296-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130274464-A1 | Arylethynyl Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274464-A1 | Arylethynyl Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8420661-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420661-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420661-B2 | Arylethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2558457-A1 | ARYLETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | GRM5, GRM1, GRM3 | GRM5 1/4885AR 536/4885OPRL1 61/4885 |
| US-20140155602-A1 | Arlethynyl Derivatives | GRM5, GRIK5, GRM1 | GRM5 1/4885AR 267/4885OPRL1 69/4885 |
| US-20130274464-A1 | Arylethynyl Derivatives | GRM5, GRM1, GRM3 | GRM5 1/4885AR 536/4885OPRL1 61/4885 |
| US-20110251169-A1 | Arylethynyl derivatives | GRM5, GRM1, GRM3 | GRM5 1/4885AR 536/4885OPRL1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.